First Manhattan
FATE icon

First Manhattan’s Fate Therapeutics FATE Stock Holding History

First Manhattan’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$1K – 1385
2018
Q3 		$1K Hold
100
– – ﹤0.01% 1360
2018
Q2 		$1K Hold
100
– – ﹤0.01% 1318
2018
Q1 		$0 Sell
100
-150
-60% -$1.44K ﹤0.01% 1401
2017
Q4 		$1K Sell
250
-1,000
-80% -$4.46K ﹤0.01% 1408
2017
Q3 		$4K Hold
1,250
– – ﹤0.01% 1317
2017
Q2 		$4K Hold
1,250
– – ﹤0.01% 1262
2017
Q1 		$5K Sell
1,250
-500
-29% -$1.83K ﹤0.01% 1262
2016
Q4 		$4K Sell
1,750
-1,500
-46% -$4.02K ﹤0.01% 1269
2016
Q3 		$10K Sell
3,250
-4,500
-58% -$10.9K ﹤0.01% 1184
2016
Q2 		$13K Buy
7,750
+3,750
+94% +$6.8K ﹤0.01% 1176
2016
Q1 		$7K Buy
4,000
+3,000
+300% +$6.18K ﹤0.01% 1207
2015
Q4 		$3K Buy
+1,000
New +$4.2K ﹤0.01% 1301
2015
Q2 		– Sell
-1,000
Closed -$4K – 1459
2015
Q1 		$4K Buy
1,000
+300
+43% +$1.49K ﹤0.01% 1332
2014
Q4 		$3K Buy
+700
New +$3.09K ﹤0.01% 1380

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan's FATE Position: Q4 2018 in Review

First Manhattan sold out of Fate Therapeutics (FATE) in Q4 2018, closing a stake of 100 shares — an estimated $1K sold.

First Manhattan first reported a position in FATE in Q4 2014 and held it in 14 quarters. The position peaked at $13K in Q2 2016. 122 funds tracked by Wall St. Rank hold FATE as of Q4 2018.

  • First Manhattan reported no remaining Fate Therapeutics position as of Q4 2018 after selling out during the quarter.
  • First Manhattan sold 100 Fate Therapeutics shares in Q4 2018, an estimated $1K.
  • First Manhattan first reported a position in Fate Therapeutics in Q4 2014 and held it in 14 quarters.
  • First Manhattan's Fate Therapeutics position peaked at $13K in Q2 2016.
  • 122 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2018.

Based on First Manhattan's 13F filing for Q4 2018, filed 30 Jan 2019.